10月16日 - ** 药物开发商 MIRA Pharmaceuticals MIRA.O股价盘前上涨 90% 至 2.52 美元
** 公司称其实验性口服药物 Mira-55 在慢性炎症性疼痛的临床前动物实验中，比注射吗啡更能缓解疼痛和减轻肿胀
** Mira-55 通过靶向 CB2 受体--MIRA，使疼痛水平恢复正常并直接减轻炎症反应
** CB2 受体在免疫细胞中表达，参与免疫反应和炎症的调节
** 公司称吗啡只能部分减轻炎症反应
** 数据支持 Mira-55 用于慢性炎症性疼痛的上市申请计划 - MIRA
** 截至上次收盘，股价年累计上涨约 16
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.